

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE 01/30/2004 100/1026-10 7134 10/768,788 Anthony J. Berno EXAMINER 02/28/2006 31662 7590 PERLEGEN SCIENCES, INC. WHALEY, PABLO S LEGAL DEPARTMENT PAPER NUMBER ART UNIT 2021 STIERLIN COURT MOUNTAIN VIEW, CA 94043 1631

DATE MAILED: 02/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No.	Applicant(s)	
		10/768,788	BERNO ET AL.	
		Examiner	Art Unit	
		Pablo Whaley	1631	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
Status				
1)	Responsive to communication(s) filed on			
·		– action is non-final.		
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is			
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4)⊠ Claim(s) <u>1-139</u> is/are pending in the application.				
	4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.				
6)□	6) Claim(s) is/are rejected.			
7)	7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-139</u> are subject to restriction and/or election requirement.				
Application Papers				
9)☐ The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 				
	2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of the certified copies not received.				
Attachment(s)				
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application (PTO-152)				
Paper No(s)/Mail Date 6) Other:				

ELECTION/RESTRICTIONS

Page 2

Restriction to one of the following inventions is required under 35 U.S.C. 121:

GROUPS

I. Claims 1-118, and 133-139 drawn to a computer-implemented method and data

processing apparatus for characterizing an interrogation position in a nucleic acid

segment, a method for determining a relative allele frequency for an interrogation

position in a nucleic acid segment, and a computer-implemented method for

characterizing a polymorphic marker in a nucleic acid, classified in class 702, subclass

19. If this specie is elected, then the below summarized specie election is further

required.

II. Claim 119-132, drawn to computer-implemented method for characterizing an

interrogation position in a nucleic acid segment, classified in class 702, subclass 019. If

this specie is elected, then the below summarized specie election is further required.

The inventions are distinct and divergent, each from the other because of the following reasons:

The inventions of Groups I and II are drawn to methods generally resulting in

characterizing an interrogation position in a nucleic acid segment. While the inventions of

Groups I and II are related, they consist of distinct steps and therefore have different modes of

operation, different functions, or different effects. In the instant case the inventions of Group I

and Group II have different effects. Methods of genetic characterization using hybridization

intensities are known in the art (Hulbert et al., Proceedings of the National Academy of Sciences

of the, 1990). Group I consists of steps using hybridization probe intensities, and characterizing

the interrogation position based on hybridization probe intensities, both of which are not present

in Group I. Steps of Group I that are not present in Group II include measures of relative allele frequency at the interrogation position in a nucleic acid segment, determining a plurality of intensities from nucelic acid segments, and determining the relative allele frequency of an interrogation position using intensity averaging equations. Furthermore, Group I consists of a data processing apparatus. Thus the burden of search is maintained as the examination process requires a search of non-patent literature, U.S. patent publications, U.S. patents, as well as foreign patent literature.

Because these inventions are distinct and divergent for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

SPECIE ELECTION REQUIREMENT

This application contains claims directed to patentably distinct species of the claimed invention. If Group I is elected, the applicant is further required to elect a species from EACH of groups A-E below. If Group II is elected, then applicant is further required to elect a single specie from EACH of groups D and E below.

Specie A: Species of phenotypic characteristics of interest are cited in claims 7, 8, 10, and 11, which are drawn to distinct therapeutic responses to clinically distinct disorders which are generally separately classified and published, and thus document undue search burden if searched together. Thus applicants are required to select one particular type of phenotypic characteristic of interest from those listed in claims 7, 8, 10, and 11.

Specie B: Species of the measure of relative allele frequency are cited in claims 50, 51, 52, 55, and 58, which are drawn to intensities determined by signal averaging, multiple signal Application/Control Number: 10/768,788

Art Unit: 1631

averaging, corrected signal averaging, and hybridization to perfect match probes, and thus

Page 4

document undue search burden if searched together. Thus applicants are required to select one

type of measure of relative allele frequency from those listed in claims 50, 51, 52, 55, and 58.

Specie C: Species of the mean intensities are cited in claims 62, 63, 110, 111, 116, and 117,

which are drawn to mathematically distinct operations, and thus document undue search burden

if searched together. Thus applicants are required to select one of the following mean

intensities:

i. arithmetic mean

ii. trimmed mean

Specie D: Species of the candidate genes are cited in claims 129-132, which are drawn to

distinct genetic sequences, and thus document undue search burden if searched together. Thus

applicants are required to select one of the following candidate genes:

i. candidate gene not previously known

ii. candidate gene previously known

Specie E: Species of the nucleotide segment positions are cited in claims 129-132, which are

drawn to distinct genetic positions, and thus document undue search burden if searched

together. Thus applicants are required to select one of the following nucleotide segment

positions:

i. Proximal to a region of a candidate gene

ii. Within a region of a candidate gene

iii. Within an untranslated region of a candidate gene

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from EACH of groups A-E above for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-6, 12-49, 64-109, 112-115, 118-128, and 133-139 are generic to the above species.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 10/768,788

Art Unit: 1631

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Pablo Whaley whose telephone number is (571)272-4425. The examiner

can normally be reached on 9:30am through 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be

obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MARJORIE A. MORAN Mayoris a. Moron 2/16/04

Page 6